Abstract:Abstract Background Before the deposition of amyloid-beta plaques and the onset of learning memory deficits, patients with Alzheimer’s disease (AD) experience olfactory dysfunction, typified by a reduced ability to detect, discriminate, and identify odors. Rodent models of AD, such as the Tg2576 and APP/PS1 mice, also display impaired olfaction, accompanied by aberrant in vivo or in vitro gamma rhythms in the olfactory pathway. However, the mechanistic relationships between the electrophysiological, biochemical and behavioral phenomena remain unclear. Methods To address the above issues in AD models, we conducted in vivo measurement of local field potential (LFP) with a combination of in vitro electro-olfactogram (EOG), whole-cell patch and field recordings to evaluate oscillatory and synaptic function and pharmacological regulation in the olfactory pathway, particularly in the olfactory bulb (OB). Levels of protein involved in excitation and inhibition of the OB were investigated by western blotting and fluorescence staining, while behavioral studies assessed olfaction and memory function. Results LFP measurements demonstrated an increase in gamma oscillations in the OB accompanied by altered olfactory behavior in both APP/PS1 and 3xTg mice at 3–5 months old, i.e. an age before the onset of plaque formation. Fewer olfactory sensory neurons (OSNs) and a reduced EOG contributed to a decrease in the excitatory responses of M/T cells, suggesting a decreased ability of M/T cells to trigger interneuron GABA release indicated by altered paired-pulse ratio (PPR), a presynaptic parameter. Postsynaptically, there was a compensatory increase in levels of GABA A R α1 and β3 subunits and subsequent higher amplitude of inhibitory responses. Strikingly, the GABA uptake inhibitor tiagabine (TGB) ameliorated abnormal gamma oscillations and levels of GABA A R subunits, suggesting a potential therapeutic strategy for early AD symptoms. These findings reveal increased gamma oscillations in the OB as a core indicator prior to onset of AD and uncover mechanisms underlying aberrant gamma activity in the OB. Conclusions This study suggests that the concomitant dysfunction of both olfactory behavior and gamma oscillations have important implications for early AD diagnosis: in particular, awareness of aberrant GABAergic signaling mechanisms might both aid diagnosis and suggest therapeutic strategies for olfactory damage in AD.

A Potential Biomarker of Preclinical Alzheimer’s Disease: the Olfactory Dysfunction and Its Pathogenesis-Based Neural Circuitry Impairments

Olfactory Bulb Biosensor Monitoring the Effect of Treatment Drugs for AD in Vitro

Potential neural substrates underlying circadian and olfactory disruptions in preclinical Alzheimer's disease

Olfactory deficit: a potential functional marker across the Alzheimer's disease continuum

Pathological features and molecular signatures of early olfactory dysfunction in 3xTg‐AD model mice

Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease

Olfactory Dysfunctions in Neurodegenerative Disorders

Disruptions of the olfactory and default mode networks in Alzheimer's disease.

Disruptions of the Olfactory and Default Mode Networks in Alzheimer's Disease

Impairment of Dendrodendritic Inhibition in the Olfactory Bulb of APP/PS1 Mice

Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models

Biomarkers in Alzheimer's Disease: Are Olfactory Neuronal Precursors Useful for Antemortem Biomarker Research?

Olfactory Deficits Induce Neurofilament Hyperphosphorylation

Functional Connectivity between the Resting-State Olfactory Network and the Hippocampus in Alzheimer’s Disease

Olfactory dysfunction and its related molecular mechanisms in Parkinson’s disease

Olfactory dysfunction and its related molecular mechanisms in Parkinson's disease

Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model

Multimodal spatiotemporal monitoring of basal stem cell-derived organoids reveals progression of olfactory dysfunction in Alzheimer's disease

An investigation of the clinical features, white matter alterations and resting-state fmri changes of olfactory dysfunction in alzheimer’s disease

Analyses of Clinical Features and Investigations on Potential Mechanisms in Patients with Alzheimer's Disease and Olfactory Dysfunction.

Anosmia, mild cognitive impairment, and biomarkers of brain aging in older adults